AI Article Synopsis

  • * The article details the creation of selective S1P1 agonists using a specific chemical structure, showing impressive selectivity and effectiveness.
  • * Two compounds, notably 19a, were tested in animal models and demonstrated significant success in reducing lymphocyte levels and treating conditions like arthritis and autoimmune encephalomyelitis.

Article Abstract

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates a multitude of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation. Because of the ability of S1P1 receptor agonists to suppress lymphocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases. In this article, the discovery of selective, direct acting S1P1 agonists utilizing an ethanolamine scaffold containing a terminal carboxylic acid is described. Potent S1P1 agonists such as compounds 18a and 19a which have greater than 1000-fold selectivity over S1P3 are described. These compounds efficiently reduce blood lymphocyte counts in rats through 24 h after single doses of 1 and 0.3 mpk, respectively. Pharmacodynamic properties of both compounds are discussed. Compound 19a was further studied in two preclinical models of disease, exhibiting good efficacy in both the rat adjuvant arthritis model (AA) and the mouse experimental autoimmune encephalomyelitis model (EAE).

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.6b00373DOI Listing

Publication Analysis

Top Keywords

s1p1 agonists
8
discovery structure-activity
4
structure-activity relationship
4
relationship sar
4
sar series
4
series ethanolamine-based
4
ethanolamine-based direct-acting
4
agonists
4
direct-acting agonists
4
agonists sphingosine-1-phosphate
4

Similar Publications

Effects of Sphingosine-1-Phosphate on the Facilitation of Peripheral Nerve Regeneration.

Cureus

November 2024

Division of Dental Anesthesiology, Faculty of Dentistry & Graduate School of Medical and Dental Sciences, Niigata University, Niigata, JPN.

This study aims to explore the role of sphingosine-1-phosphate (S1P) in peripheral nerve regeneration after injury. S1P is a crucial metabolite involved in cell migration, inflammation, and nerve regeneration. In this research, six-week-old male Sprague-Dawley rats (total n=18) underwent transection of the inferior alveolar nerve (IAN) and were divided into three groups: S1PR agonist (FTY720) (n=6), saline control (n=6), and S1P1R antagonist (n=6).

View Article and Find Full Text PDF

Sphingosine 1-phosphate (S1P) is a lysosphingolipid with antiatherogenic properties, but mechanisms underlying its effects remain unclear. We here investigated atherosclerosis development in cholesterol-rich diet-fed LDL receptor-deficient mice with high or low overexpression levels of S1P receptor 1 (S1P1) in macrophages. S1P1-overexpressing macrophages showed increased activity of transcription factors PU.

View Article and Find Full Text PDF

Sphingosine 1-phosphate receptor subtype 1 (S1P) activity in the course of Alzheimer's disease.

Neurobiol Dis

November 2024

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), B° Sarriena s/n, 48940 Leioa, Spain; Neurodegenerative Diseases, BioBizkaia Health Research Institute, Bizkaia, Spain, 48903 Barakaldo, Spain.

Some specific lipid molecules in the brain act as signaling molecules, neurotransmitters, or neuromodulators, by binding to specific G protein-coupled receptors (GPCR) for neurolipids. One such receptor, sphingosine 1-phosphate receptor subtype 1 (S1P), is coupled to G proteins and is involved in cell proliferation, growth, and neuroprotection. S1P constitutes an interesting target for neurodegenerative diseases like multiple sclerosis and Alzheimer's disease (AD), in which changes in the sphingolipid metabolism have been observed.

View Article and Find Full Text PDF

Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice.

View Article and Find Full Text PDF

Sphingosine-1-phosphate receptor 1/5 selective agonist alleviates ocular vascular pathologies.

Sci Rep

April 2024

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.

Ocular abnormal angiogenesis and edema are featured in several ocular diseases. S1P signaling via S1P1 likely is part of the negative feedback mechanism necessary to maintain vascular health. In this study, we conducted pharmacological experiments to determine whether ASP4058, a sphingosine 1-phosphate receptor 1/5 (S1P1/5) agonist, is useful in abnormal vascular pathology in the eye.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: